Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human trial data
PubMed 36230883 · doi:10.3390/cancers14194960
What was done
This review evaluates preclinical and clinical developments across different nanoparticle families designed to cross the blood-brain barrier and improve drug delivery for glioblastoma multiforme.
What was found
The abstract reports contextual survival statistics for glioblastoma (overall survival below 2 years, 5-year survival rate under 7%), but provides no quantitative results or comparative effect sizes for the discussed nanoparticle therapies.
Why it matters
Current standard treatments fail to substantially improve glioblastoma outcomes largely due to poor blood-brain barrier penetration; nanoparticle-based delivery could potentially enhance drug targeting while minimizing systemic toxicity.
Limits
The paper is a narrative review without reported systematic search methods or direct clinical data. The abstract provides no quantitative metrics, trial sample sizes, or toxicity profiles for specific nanoparticle formulations.
Cited by
- supports Glioblastoma brain tumors are uniformly fatal.